MedTrace Logo

The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy

NCT04585841 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-07-24

No results posted yet for this study

Summary

An intervention study on the effect of cannabidiol on lean body mass in cancer patients receiving chemotherapy, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark. Fat free mass will be measured by bioimpedance spectroscopy. As secondary outcomes protein and energy intake, nausea, taste alterations and life quality will be assessed by oral interviews and questionnaires.

Conditions

  • Lean Body Mass
  • Cannabis
  • Cancer
  • Nausea
  • Cachexia
  • Emesis
  • Appetitive Behavior

Interventions

DRUG

Cannabidiol

Patients will receive cannabidiol in the period of time they receive chemotherapy.

Sponsors & Collaborators

  • Zealand University Hospital

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Jens Rikardt Andersen, MD · University of Copenhagen

  • Sebastian W Nielsen, MD · Zealand University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-08-30
Completion
2022-11-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04585841 on ClinicalTrials.gov